Company intelligence / Profile preview

Antev

London, United Kingdom

Ownership: Public · MDCX
Development stage: Phase 3

Overview

Phase 2b open-label study in 40 men for advanced prostate cancer in high cardiovascular risk patients, and Phase 2b study testing Teverelix in 390 men across the US and EU for AUR[4]

Therapeutic areas: Men's HealthOncologyWomen's Health
Modalities: Peptides (GnRH antagonist)
Industry: Biotech

Drug pipeline

1 asset

teverelix

Phase 3

Indications: Prostate cancer with high cardiovascular risk, Acute urinary retention due to enlarged prostate

Financials

Market cap: $3.6M
Total revenue: $0
Enterprise value: $8.1M

Beyond the preview

Go deeper on Antev.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antev.

Explore the full profile